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Upon antigen recognition and co-stimulation, T
lymphocytes upregulate the metabolic machinery
necessary to proliferate and sustain effector func-
tion. This metabolic reprogramming in T cells regu-
lates T cell activation and differentiation but is not
just a consequence of antigen recognition. Although
such metabolic reprogramming promotes the differ-
entiation and function of T effector cells, the differen-
tiation of regulatory T cells employs different meta-
bolic reprogramming. Therefore, we hypothesized
that inhibition of glycolysis and glutamine meta-
bolism might prevent graft rejection by inhibiting
effector generation and function and promoting
regulatory T cell generation. We devised an anti-
rejection regimen involving the glycolytic inhibitor
2-deoxyglucose (2-DG), the anti-type II diabetes
drug metformin, and the inhibitor of glutamine meta-
bolism 6-diazo-5-oxo-L-norleucine (DON). Using this
triple-drug regimen, we were able to prevent or delay
graft rejection in fullymismatched skin and heart allo-
graft transplantation models.
INTRODUCTION
Advances in immunosuppressive regimens have played an
essential role in driving forward the field of organ transplantation
(Sayegh and Carpenter, 2004). However, long-term use of
immunosuppressants results in a broad range of co-morbidity.
For example, calcineurin inhibitors are associated with hyper-
lipidemia, hyperglycemia, neuro- and nephrotoxicity, and an
increased risk of malignancy (Arnold et al., 2013; Crutchlow
and Bloom, 2007; Guba et al., 2004; Hoorn et al., 2012; Roodnat
et al., 2014). In addition, such agents inhibit negative regulatory760 Cell Reports 13, 760–770, October 27, 2015 ª2015 The Authorsand tolerance-inducing responses (Wu et al., 2012). That is, the
calcineurin inhibitors are truly immunosuppressive in that they
inhibit both activating and inhibitory signaling pathways (Powell
and Zheng, 2006). As such, whereas the ultimate goal of anti-
rejection strategies is to induce immune tolerance in the absence
of long-term immunosuppression, current treatment regimens
thwart this goal by inhibiting the induction of tolerance. There-
fore, new approaches to preventing graft rejection are required.
Recently, metabolic signaling pathways have been shown to
play critical roles in dictating the outcomes of T cell responses
(Pollizzi and Powell, 2014; Waickman and Powell, 2012; Yang
and Chi, 2012). The coordination of metabolism reprogramming
and T cell function reflects the ability of how low-frequency anti-
gen-specific naive T cells rapidly expand in response to a path-
ogen (Powell et al., 2013). In the presence of oxygen, naive or
resting T cells rely on mitochondrial oxidative phosphorylation
(OXPHOS) to generate energy necessary for immune surveil-
lance (Pearce et al., 2013). In contrast, both CD4+ and CD8+
effector T cells employ aerobic glycolysis to meet their biosyn-
thetic demands (Jones and Thompson, 2007; Pearce et al.,
2013). This use of glycolysis in the presence of oxygen was first
described by Otto Warburg in cancer cells (Warburg, 1956) and
was subsequently found to be important in activated T cells
(Warburg et al., 1958). It has been proposed that aerobic glycol-
ysis permits the generation of the substrates necessary for the
generation of amino acids, nucleic acids, and lipids, all of which
are crucial for activation and proliferation (Vander Heiden et al.,
2009). Essential for this activation-induced glycolytic response
is glucose uptake (Cham et al., 2008; Cham and Gajewski,
2005). Indeed, the increased expression of the glucose trans-
porter GLUT1 on the cell surface is a critical aspect of T cell re-
ceptor (TCR)-induced activation (Jacobs et al., 2008). Similarly,
the uptake andmetabolism of amino acids, especially glutamine,
is essential for T cell activation (Carr et al., 2010). Glutamine
deprivation blocks T cell proliferation and cytokine production
(Carr et al., 2010). While the considerations depicted above
reflect the metabolic needs of T cells during activation and
explosive proliferation, what has also become apparent is that
different T cell subsets require different metabolic programs.
For example, Th1, Th2, and Th17 effector T cells have been
found to depend on glucose uptake and glycolysis. Alternatively,
regulatory T cells (Tregs) are not dependent upon glycolysis and
appear to rely more on lipid oxidation to generate energy (Huynh
et al., 2015; Michalek et al., 2011). Blocking glycolysis inhibits
effector development but promotes Treg formation (Shi et al.,
2011). Furthermore, CD4+ effector T cells with GLUT1 deficiency
are impaired in proliferation and function in vivo, whereas Tregs
are enriched and functionally unaffected (Macintyre et al., 2014).
Likewise, glutamine is critically required by naive CD4+ T cells to
differentiate to Th1 and Th17 effector T cells, but not to Tregs
(Nakaya et al., 2014). Thus, strategies designed to inhibit meta-
bolic reprogramming to prevent naive T cells from activating
and differentiating into effector T cells might provide a means
to inhibit transplant rejection. In this study, we demonstrate
that combined inhibition of glycolysis and glutamine metabolism
leads to a profound suppression in CD4+ andCD8+ effector T cell
responses while preserving mechanisms of immune regulation.
We propose that this anti-metabolic regimen represents a prom-
ising strategy to promote allograft survival.
RESULTS
Blocking Glycolysis Inhibits Activation-Induced T Cell
Proliferation and Cytokine Production
To assess the effect of metabolic inhibitors on the metabolic
changes of resting T cells in response to stimulation, we
measured the two intrinsic cellular bioenergetic parameters,
the oxygen consumption rate (OCR) and the extracellular acid-
ification rate (ECAR), with an XF96 extracellular flux analyzer
(Seahorse Bioscience). The OCR is an indicator of mitochondrial
OXPHOS, and the ECAR is predominantly a measure of lactic
acid formed during glycolytic energy metabolism and thus re-
flects overall glycolytic flux. Naive 5C.C7 CD4+ T cells were
incubated with pigeon cytochrome c (PCC) peptide for 48 hr
and then expanded and rested in IL-2 for an additional 5 days
to generate previously activated CD4+ cells. After measuring
the baseline bioenergetics of these resting CD4+ cells, cells
were re-stimulated with anti-CD3/CD28 (Figures 1A and 1B).
Upon activation, the T cells exhibited a marked increase in the
ECAR and a modest increase in the OCR in response to anti-
CD3/CD28 (Figures 1A and 1B). Upon reaching the peak of
glycolytic flux, metabolic inhibitors were administered to the
cells. 2-DG is an ATP-depleting agent and glucose analog that
inhibits hexokinase, the first enzyme in the glycolytic pathway
(Rowe et al., 2013). Adding 2-DG led to a sharp decrease in
ECAR levels and an insignificant increase in the OCR (Figures
1A and 1B), reflecting that 2-DG inhibited glycolysis but mini-
mally affected OXPHOS (Cheng et al., 2012; Yamasaki et al.,
2011).
Metformin is a commonly used oral hypoglycemic that acti-
vates AMPK, inhibits mitochondrial respiratory complex I, and
promotes fatty acid oxidation (Buzzai et al., 2007; El-Mir et al.,
2000). Consistent with its ability to inhibit complex I (El-Mir
et al., 2000), the addition of metformin led to a marked suppres-
sion of the OCR and an increase in the ECAR (Figures 1A andC1B). It has been shown that organic cation transporters mediate
uptake of metformin (Graham et al., 2011). Interestingly, we
observed increased expression of organic cation transporter 1
(OCT1) upon T cell activation (Figure S1). These findings suggest
that metformin will preferentially affect activated T cells, which in
turn express more OCT1.
The concomitant use of 2-DG and metformin together has
been shown to potentiate the inhibition of glycolysis in tumor
cells (Cheng et al., 2014; Cheong et al., 2011). Indeed, when
combined with metformin, 2-DG inhibits the ECAR in T cells
more effectively than when employed alone (Figure 1A). In addi-
tion, the combination of 2-DG and metformin led to an OCR
lower than that of the no-treatment group but higher than that
of metformin alone (Figure 1B). Thus, similar to observations in
tumor cells, combining 2-DG and metformin leads to a profound
decrease in glycolysis in activated T cells.
Given the critical role of glycolysis in promoting T cell effector
function, we next sought to determine the effect of 2-DG and
metformin on T cell proliferation and cytokine production. To
this end, splenocytes from wild-type (WT) C57BL/6 mice
were stimulated with anti-CD3 in the presence of media con-
trol, 2-DG alone, metformin alone, or 2-DG + metformin for
72 hr. Initial extensive titration studies demonstrated that 2-
DG or metformin monotherapy inhibited T cell proliferation
and cytokine production in a dose-dependent manner (data
not shown). Importantly, consistent with their combined meta-
bolic effects, the combination of 2-DG and metformin showed a
more significant inhibition of cell proliferation and IFN-g pro-
duction of activated CD4+ and CD8+ T cells than either com-
pound alone (Figures 1C and 1D). Together, these data suggest
that 2-DG in combination with metformin potently inhibit both
metabolic reprogramming and proliferation/cytokine produc-
tion in activated T cells.
Combined Inhibition of Glycolysis and Glutamine
Metabolism Profoundly Abrogates Activation-Induced T
Cell Proliferation and Cytokine Production
Upon activation, glutamine oxidation and glycolysis increase to
meet biosynthetic demand, allowing for continued tricarboxylic
acid (TCA) flux (MacIver et al., 2013). Consequently, T cell activa-
tion, differentiation, and function are critically dependent upon
adequate glutamine availability (Carr et al., 2010; Nakaya et al.,
2014). To this end, upon activation, T cells coordinately increase
the expression of glutamine transporters and glutaminase activ-
ity required for glutamine oxidation (Carr et al., 2010; Nakaya
et al., 2014).
6-Diazo-5-oxo-L-norleucine (DON) is a glutamine analog that
inhibits multiple targets in the glutamine metabolic pathway,
including glutaminase and glutamine transporters (Thomas
et al., 2014). To explore the role of glutaminase activity in
T cell activation, naive CD4+ T cells were stimulated with anti-
CD3/CD28 in medium with or without metabolic inhibitors for
24 hr. The glutaminase activity of these CD4+ T cells was deter-
mined using a radiolabeled assay as described previously
(Thomas et al., 2013). We observed that activated T cells
exhibited increased glutaminase activity compared to naive
T cells (Figure 2A), indicating metabolic reprogramming toward
glutaminolysis. As expected, glutaminase activity of activatedell Reports 13, 760–770, October 27, 2015 ª2015 The Authors 761
Figure 1. 2-DG Combined with Metformin Inhibits T Cell Responses through Suppression of Glycolysis
(A and B) The ECAR andOCR of resting CD4+ cells measured in real time under basal conditions and in response to anti-CD3/CD28/cross-linking IgG1 (anti-CD3,
2 mg/ml; anti-CD28, 2 mg/ml; cross-linking IgG1, 1 mg/ml) with or without the presence of individual or combination of drugs (2-DG, 10mM;metformin, 50mM). Bar
graphs display data of ECAR and OCR measured at the endpoint of the experiment (205 min). Data are shown as mean ± SEM of five measurements.
(C and D) Naive splenocytes labeled with cell proliferation dye eFluor 670 were stimulated with anti-CD3 in in the presence of media control, 2-DG alone,
metformin alone, or 2-DG+metformin (2-DG, 0.6mM;metformin, 1mM). (C) 24-hr IFN-g secretion to supernatants was interrogated by ELISA. Data are shown as
mean ± SEM of three independent samples. (D) 72-hr eFluor dilution of CD4+ and CD8+ T cells.
n.s., not significant, *p < 0.05, **p < 0.01, ****p < 0.0001 (Student’s t test). Data are representative of at least two independent experiments.T cells was significantly abrogated in the presence of DON (Fig-
ure 2A), and this inhibition was not affected by the presence of
the glycolytic inhibitors (Figure 2A). Furthermore, when cultured
with DON, activated CD4+ and CD8+ T cells had decreased IFN-
g production and proliferation (Figures 2B and 2C). Having
confirmed previous studies showing that blocking glutamine
metabolic pathway was also capable of suppressing T cell re-
sponses (Carr et al., 2010), we next wanted to investigate
whether dual inhibition of glycolysis and glutamine metabolism
had an additional effect on inhibiting T cell proliferation and
function. To this end, we combined 2-DG, metformin, and
DON as a triple-therapy regimen. Indeed, triple therapy had a
more profound effect on suppressing T cell IFN-g production
and proliferation than only 2-DG and metformin or DON alone762 Cell Reports 13, 760–770, October 27, 2015 ª2015 The Authors(Figures 2B and 2C). Notably, the decrease in function was
not because of a decrease of cell viability (Figure S2). In addi-
tion, although glutamate can be further catabolized to fuel
the TCA cycle and ATP production (Pearce et al., 2013), in extra-
cellular flux analysis, we did not find that adding DON (individu-
ally or combined with 2-DG and metformin) had an obvious
impact on either OXPHOS or glycolytic flux of activated cells
(Figure S3). Similarly, while 2-DG, metformin, and DON individ-
ually had minimal effects on de novo lipid synthesis, triple
therapy resulted in marked suppression of de novo lipid synthe-
sis (Figure 2D). When glycolysis is blocked in conjunction with
glutamine-dependent biosynthetic pathways, the decreased
acetyl-coA level results in decreased lipid production neces-
sary for increased membrane formation essential to facilitate
Figure 2. Combined Inhibition of Glycolysis and Glutaminolysis Profoundly Suppresses T Cell Responses
(A) Glutaminase activity of CD4+ T cells cultured for 24 hr in different conditions (anti-CD3, 2 mg/ml; anti-CD28, 2 mg/ml; DON, 5 mM; 2-DG, 0.6 mM; metformin,
1 mM). Data are shown as mean ± SEM of three independent experiments.
(B and C) Naive WT C57BL/6 splenocytes labeled with eFluor 670 and stimulated with anti-CD3 in medium containing indicated metabolic inhibitors (DON, 5 mM;
2-DG, 0.6 mM; metformin, 1 mM). (B) 24-hr IFN-g secretion to supernatants as interrogated by ELISA. Data are shown as mean ± SEM of three independent
samples.
(C) Proliferation of CD4+ and CD8+ T cells at 72 hr measured by dilution of eFluor 670. n.s., not significant, **p < 0.01, ***p < 0.001, ****p < 0.0001 (Student’s t test).
Data are representative of at least two independent experiments.
(D) 3H-acetate incorporation into lipids in preactivated and stimulated CD4+ T cells (anti-CD3, 1 mg/ml; anti-CD28, 2 mg/ml; cross-linking, 0.75 mg/ml) with the
presence of 2DG, metformin, DON, or in combination (2DG, 5 mM; metformin, 30 mM; DON, 60 mM). Data are shown as mean ± SEM of three independent
samples. ***p < 0.001 (ANOVA). Data are representative of two independent experiments.
(E) The phosphorylation state of the S6 ribosomal protein was measured in CD4+ T cells after 30-min stimulation (anti-CD3, 1 mg/ml; anti-CD28, 2 mg/ml; cross-
linking 0.75 mg/ml) with the presence of rapamycin, PP242, andmetabolic inhibitors (rapamycin, 1 mM; pp242, 1 mM; 2DG, 5mM,metformin, 30mM; DON, 60 mM).
Data are representative of two independent experiments.proliferation. Moreover, triple therapy was associated with a
decrease in mTORC1 activation as measured by S6 ribosomal
protein phosphorylation, which correlates with previous find-
ings (Powell et al., 2013) that suppression of mTORC1 results
in decreased T cell effector function (Figure 2E). Therefore, by
interrogating the inhibition of metabolic pathways known to
play a critical role in T cell activation and function, we have
determined that the inhibition of activation-induced T cell prolif-
eration and function was most effective by simultaneously
blocking glycolysis (with 2-DG and metformin) and glutamine
metabolism (with DON).CInhibition of Glycolysis and Glutamine Metabolism
Preferentially Suppresses the Proliferation and
Function of Antigen-Specific CD4+ Effector T Cells
Compared to Tregs In Vivo
Given the observation that inhibition of glycolysis and glutamine
metabolism suppresses the activation of T cells in vitro, we next
wanted to examine this paradigm in an antigen-specific manner
in vivo. To test the ability of metabolic inhibitors to mitigate CD4+
effector T cell responses, Thy1.1+ CD4+ ovalbumin (OVA)-spe-
cific (OT-II) TCR transgenic T cells were adoptively transferred
into Thy1.2+ WT mice that were concomitantly infected withell Reports 13, 760–770, October 27, 2015 ª2015 The Authors 763
vaccinia-OVA, a recombinant vaccinia virus carrying chicken
OVA on day 0. Themicewere then treated with PBS (vehicle con-
trol), 2-DG + metformin, or 2-DG + metformin + DON (triple ther-
apy) for 3 days, and the expansion of the OVA-specific Thy1.1+
CD4+ T cells was interrogated on day 4. Mice treated with 2-
DG + metformin demonstrated a marked decrease in the expan-
sion of the antigen-specific Thy1.1+ CD4+ T cells, which was
even further reduced with the triple therapy (Figure 3A). In
addition, the triple-therapy regimen in vivo strongly inhibited an-
tigen-specific IFN-g production of splenocytes upon re-chal-
lenge with peptide ex vivo (Figure 3B). Triple therapy also led
to a significantly higher frequency of Foxp3+ CD4+ T cells (Fig-
ure 3C), indicating a preservation of this mechanism of immune
regulation. Notably, the expansion and absolute number of
Thy1.1+ Foxp3+ T cells was decreased in the triple-therapy-
treated mice when compared to the untreated mice. This indi-
cates that as is the case for effector cells, the expansion of
Foxp3+ T cells in response to antigen requires glycolysis and
glutamine. However, the ratio of OVA-specific Thy1.1+ regulatory
T cells to effector cells was increased in treatedmice (Figure 3D).
Together, these results demonstrate that triple therapy had the
most robust effect on inhibiting CD4+ T cell proliferation and
cytokine production upon antigen recognition, while the differen-
tiation into antigen-specific regulatory T cells was relatively
preserved.
Inhibition of Glycolysis and Glutamine Metabolism
Suppresses the Proliferation and Function of
Antigen-Specific CD8+ T Cells
Next, we examined the ability of the metabolic inhibitors to block
antigen-specific CD8+ T cell responses. To this end, Thy1.1+
CD8+ OVA-specific (OT-I) TCR transgenic T cells were adop-
tively transferred into Thy1.2+ WT mice, and the mice were in-
fected with vaccinia-OVA and treated with metabolic inhibitors
(the same regimen used in OT-II experiments). As was the
case of CD4+ T cells, treatment of the mice with triple therapy
led to a more profound inhibition of the expansion of the anti-
gen-specific Thy1.1+ CD8+ T cells than 2DG + metformin (Fig-
ure 3E) or any compound alone (data not shown). Additionally,
this combination of anti-metabolic therapy strongly inhibited
the generation of IFN-g-secreting CD8+ T cells (Figure 3F). The
decreased frequency and function of Thy1.1+ CD8+ T cells was
also reflected by the amount of IFN-g secreted by splenocytes
re-stimulated ex vivo with class I OVA peptide (Figure 3G).
Having demonstrated the ability of inhibitors of glycolysis and
glutamine metabolism to mitigate the expansion and function
of exogenous effector T cells, we next examined the effect of
anti-metabolic regimen on endogenous effector CD8+ T cells
with an in vivo cytotoxicity (CTL) assay. Mice were immunized
with vaccinia-OVA and treated with PBS (vehicle control),
2DG +metformin, or triple therapy for 7 days, then carboxyfluor-
escein diacetate succinimidyl ester (CFSE)-labeled target
cells were injected on day 8 and percent of specific killing was
evaluated 10 hr later. We observed that most (96% ± 2%) of
the OVA-peptide-pulsed target cells were preserved in the
mice receiving triple therapy, whereas 78% ± 5% and 45% ±
10% of the target cells were eliminated in mice receiving PBS
and 2-DG+metformin treatment, respectively (Figure 3H). These764 Cell Reports 13, 760–770, October 27, 2015 ª2015 The Authorsdata suggest that the development of effective cytotoxic T lym-
phocytes is suppressed by the inhibition of glycolysis and gluta-
mine metabolism.
Metabolic Inhibitors Promote Allograft Acceptance in
Mouse Models of Skin and Heart Transplantation
Having demonstrated the ability of combined anti-metabolic
therapy to inhibit anti-viral responses in vivo, we next investi-
gated whether anti-metabolic therapy could prolong allograft
survival by using a skin transplantation model involving C57BL/
6 mice receiving allogenic skin grafts from BALB/c mice. We
found a significantly prolonged graft median survival time
(MST) for mice that received 2-DG + metformin or DON alone
compared to those that received no treatment (13 versus
11 days, p = 0.0048 and 22 versus 11 days, p = 0.0019, respec-
tively) (Figure 4A). However, blocking both glycolysis and gluta-
mine metabolism with triple therapy resulted in a marked in-
crease of skin graft survival compared to no treatment (MST 40
versus 11 days, p < 0.0001) (Figure 4A). In addition, the appear-
ance and histology of skin grafts from the triple-therapy group
exhibited no evidence of tissue destruction, more intact tissue
alignment, and less infiltration of inflammatory cells (Figure 4B).
For comparison, the MST of this fully allogeneic skin allograft
under the treatment of FK506 or cyclosporine has previously
been reported to be less than 20 days (Lagodzinski et al.,
1990). Likewise, in our own hands, median graft survival is
16 days using rapamycin monotherapy for immunosuppres-
sion (data not shown).
Finally, we employed this triple-therapy regimen in a BALB/c
to C57BL/6 heart transplantation, which is a vascularized solid
organ transplantation model. Strikingly, when recipient mice
were treated with anti-metabolic triple therapy, the grafted
hearts continued beating for more than 100 days post-transplan-
tation without rejection (Figure 4C). Likewise, the cardiac grafts
from treatment group exhibited much healthier microscopic
morphology with no evidence of necrosis, fibrosis, or lympho-
cyte infiltration (Figure 4D). Together, these data support the
notion that the inhibition of glycolysis and glutamine metabolic
pathways represents a potent means to prevent acute rejection
and promote long-term graft acceptance.
DISCUSSION
In this study, we have defined a approach to prevent transplan-
tation graft rejection by inhibiting metabolic pathways necessary
for effector T cell function. This approach is based upon the
emerging understanding that metabolic reprogramming in
T cells is not simply the result of T cell activation, but rather plays
a critical role in regulating T cell differentiation and function
(Jones and Thompson, 2007; MacIver et al., 2013). The thera-
peutic index of our approach relies on the extraordinary meta-
bolic requirements of effector T cell response that is distinct
from the more flexible and adaptive ordinary T cell metabolic
network. As such, even though the inhibitors employed are rela-
tively nonspecific, we achieve relative cellular selectivity based
upon the extraordinary metabolic demands of the effector
T cells. That is, while glycolysis and glutamine are clearly impor-
tant for all cells, the markedly enhanced reliance of effector
Figure 3. Metabolic Inhibitors Suppress the Proliferation and Function of Antigen-Specific T Cells while Increasing the Relative Frequency of
Tregs In Vivo
(A–D) OT-II (Thy1.1+) CD4+ T cells were adoptively transferred into WT (Thy1.2+) recipient mice. The recipients were infected with OVA-expressing vaccinia virus
and treated with vehicle, 2-DG + metformin, or 2-DG + metformin + DON (2-DG, 500 mg/kg once daily; metformin, 150 mg/kg once daily; DON, 1.6 mg/kg once
every other day) for 3 days. Splenocytes from the recipients were harvested at day 4 to interrogate the frequency of antigen-specific T cells and regulatory T cells.
(A) Percentage of Thy1.1+ cells relative to CD4+ cells were analyzed by flow cytometry (left) and plotted as cumulative data (right). (B) OT-II cells were rechallenged
with OVA peptide class II (10 mg/ml) ex vivo for 24 hr. The supernatants were interrogated for IFN-g production by ELISA. Data are mean ± SEM (n = 6). (C)
Percentage of Foxp3+ cells relative to CD4+ cells (left) and plotted as cumulative data (right). (D) The ratio of OVA-specific Foxp3+ T cells to effector cells.
(E–G) OT-I (Thy1.1+) CD8+ T cells were adoptively transferred into WT (Thy1.2+) recipient mice. The hosts were infected with vaccinia-OVA and treated
with vehicle, 2-DG + metformin, or triple therapy for 5 days. Host splenocytes were harvested at day 6 to interrogate the proliferation and function of antigen-
specific CD8+ T cells. (E) The percentage Thy1.1+ cells relative to CD8+ cells was analyzed by flow cytometry (left) and plotted as cumulative data (right). (F) The
percentage IFN-g-producing cells relative to CD8+ cells (left) and plotted as cumulative data (right). (G) OT-I cells were rechallenged with OVA peptide class I
(10 mg/ml) ex vivo for 24 hr. The supernatants were interrogated for IFN-g production by ELISA. Data are mean ± SEM (n = 5–6).
(H) The ability of metabolic inhibitors to suppress endogenous effector CD8+ T cell development was assessed with an in vivo CTL assay. Percent of specific
killing was determined at 10 hr after transferring target cells. Data are mean ± SEM (n = 3 mice/group). Each symbol represents an individual mouse.
Horizontal lines indicate mean ± SEM. n.s., not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (Student’s t test). Data are representative of more than
three independent experiments.
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Figure 4. Metabolic Inhibitors Promote Allograft Survival
(A) BALB/c to C57BL/6 skin graft survival, as monitored daily by assessment of macroscopic signs of rejection.
(B) Representative photomicrographs of skin graft histology (H&E staining) on post-transplant days 7 and 40 under an optical microscope (outlet,3100; inlet:3
200).
(C) BALB/c to C57BL/6 heart graft survival, as monitored daily by palpation of heart beating.
(D) Representative photomicrographs of cardiac graft histology (H&E staining) on indicated post-transplant day under an optical microscope (outlet,3200; inlet,
3400). The anti-metabolic treatment was started from the day of graft (day 0) until rejection in both models. The dosages of all drugs were the same as described
in Figure 3.
**p < 0.01, ****p < 0.001 (log-rank analysis). Data are representative of two independent experiments.T cells on these pathways makes them relatively selective to
treatment with these relatively nonselective inhibitors. Along
these lines, T regulatory cells were more resistant to inhibition
of glycolysis and glutamine. Such an observation is consistent
with reports that unlike effector T cells, T regulatory cells rely
more on oxidative phosphorylation and lipid oxidation and in
fact glycolysis inhibits their functionality (Huynh et al., 2015).
Previous studies by our lab and others have demonstrated the
importance of mTOR in regulating T cell activation, differentia-
tion, and function (Powell et al., 2012). Furthermore, we and
others have demonstrated that the ability of mTOR to regulate
T cells is in part mediated by the role of mTOR signaling onmeta-
bolic reprogramming (Pollizzi et al., 2015; Pollizzi and Powell,
2014). Consequently, in this current report, we sought to regulate
T cell function by directly targeting metabolic pathways. Indeed,
our triple therapy led to a marked decrease in the biosynthetic
capabilities of the effector T cells. This in turn inhibited both
expansion of effector T cells as well as their function. Interest-
ingly, in as much as nutrient availability promotes mTOR activity,
this approach also led to a decrease in mTOR activity. Thus, our
approach not only inhibited metabolic programs but also poten-
tially the ability of mTOR to promote ‘‘immunologic reprogram-
ming’’ independent of metabolism.
In our study, inhibiting glycolysis by the combination of 2-DG
and metformin was not sufficient to prevent acute rejection or
induce long-term tolerance in a fully major histocompatibility
complex (MHC)-mismatched transplantation model. Inhibition
of glutamine metabolism also blocks effector T cell differentia-
tion, proliferation, and function (Carr et al., 2010; Nakaya et al.,766 Cell Reports 13, 760–770, October 27, 2015 ª2015 The Authors2014). Thus, we integrated DON, an inhibitor of glutamine meta-
bolism, into our protocol. Ultimately, the combination of inhibit-
ing glycolysis and glutamine pathways provided the most robust
protection against graft rejection. Overall, we found that
including metformin (which inhibits complex I of oxidative phos-
phorylation and also has the ability to potentiate the effects of
2-DG in terms of inhibiting glycolysis) further improved our
regimen. The doses and combinations of these agents were
determined initially in in vitro titration experiments (data not
shown). We hypothesize that targeting multiple metabolic path-
ways not only enhanced the efficacy of our regimen but also
enabled us to use lower doses of each compound, thus mini-
mizing potential side effects. Additionally, we propose that
the relative cellular selectivity based on metabolic demand not
only was observed for cells of the immune system but also
contributed to the relative lack of side effects observed. By
tracking body weight and fur ruffling as markers of overall health
of transplant recipient mice, in some cases for more than
100 days, we did not observe any systemic sickness ormorbidity
associated with the treatment regimen. Notably, the compounds
employed in our study have all been studied in patients (Franciosi
et al., 2013; Raez et al., 2013; Sullivan et al., 1988). Thus,
we believe that our combination treatment strategy might be
readily translated into the clinic. In previous trials using 2-DG
or DON or metformin for the treatment of cancer, the efficacy
was not as striking as what we have observed in using these
agents for transplant rejection (Raez et al., 2013; Sullivan et al.,
1988; Tsilidis et al., 2014). We believe that this is because,
although T effector cells and cancer cells both employ Warburg
metabolism,mutations in tumors enable them tomore effectively
become resistant to these agents.
Steroids and calcineurin inhibitors remain the backbone of
most current post-transplantation regimens. Steroids have
multiple adverse effects, such as increased risk of infection, hy-
perglycemia, accelerated atherosclerosis, and gastrointestinal
bleeding, while calcineurin inhibitors are associated with neuro-
toxicity and nephrotoxicity, as well as risk of infection and an
increased risk of cancer (Arnold et al., 2013; Crutchlow and
Bloom, 2007; Guba et al., 2004; Hoorn et al., 2012; Roodnat
et al., 2014). In this regard, we propose that our anti-metabolic
regimen has certain advantages over conventional treatments
in terms of avoiding some of these side effects. First, one poten-
tial advantage of anti-metabolic therapy is that it will promote
a favorable systemic metabolic profile. Indeed, the metabolic
inhibitors employed counteract some of the metabolic abnor-
malities associated with current immunosuppression, such as
increased blood glucose and triglycerides. Second, a major in-
fectious complication of immunosuppression for transplantation
is cytomegalovirus (CMV) infection. Interestingly, the agents em-
ployed in our anti-metabolic approach have been shown to
inhibit viral replication (Chambers et al., 2010). Third, while calci-
neurin inhibitors are associated with an increased risk of devel-
oping neoplasms (Guba et al., 2004), targeting both glycolysis
and glutamine pathways inhibits the growth of tumor cells
(Cheng et al., 2014; Cheong et al., 2011; Lim et al., 2014; Willems
et al., 2013). Also, calcineurin inhibitors can block the induction
of immunologic tolerance in part by preventing T cell anergy
and inhibiting the generation of regulatory T cells (Powell and
Zheng, 2006). The metabolic inhibitors employed in our study
both promote anergy and T regulatory cell generation (Figure 3C;
Zheng et al., 2009). However, metabolic therapy alone was not
sufficient to completely prevent skin allograft rejection. Further,
even though we observed 100% heart graft survival (Figure 4C)
while the mice were being treated, preliminary studies indicate
that stopping therapy resulted in the eventual rejection of the
hearts 80 days later (data not shown). To this end, we are
actively pursuing integrating tolerance inducing therapy such
as costimulatory blockade with our anti-metabolic regimen (Bes-
tard et al., 2011; Lo et al., 2014; Oderup et al., 2006; Pilon et al.,
2014).
In conclusion, we have defined an approach to prevention of
graft rejection by inhibiting metabolic pathways necessary for
effector T cell function. The differential metabolic requirements
of effector and regulatory T cells reveal a therapeutic window
to simultaneously inhibit rejection and promote tolerance. Future
studies combining anti-metabolic therapy with tolerance-in-
ducing regimens such as co-stimulatory blockade and Treg ther-
apy have the potential to promote long-term graft acceptance in
the absence of long-term immunosuppression.
EXPERIMENTAL PROCEDURES
Mice
Mice were kept in accordance with guidelines of the Johns Hopkins University
Institutional Animal Care and Use Committee. 5C.C7 mice (RAG2–/– CD4+
TCR-transgenic mice, which recognize Pigeon cytochrome c [PCC]) were
from Taconic Farms. OVA-specific OT-I and OT-II TCR transgenic mice from
The Jackson Laboratory were bred to Thy1.1+ backgrounds. C57BL/6C(Thy1.2+, H-2b) and BALB/c (H-2d) mice were obtained from The Jackson
Laboratory.
Antibodies and Reagents
The following antibodies for flow cytometry were from BD Biosciences:
anti-CD4 (RM4-5), anti-CD8 (Ly-3), anti-IFN-g (XMG1.2), and anti-Thy1.1
(OX-7). Anti-Foxp3 (FJK-16 s) was from eBioscience. Class I OVA peptide
and class II OVA peptide were obtained from AnaSpec. PCC peptide
81–104 was synthesized at Johns Hopkins University. Rabbit polyclonal
antibody against mouse OCT1 (SLC22A1, ab55916) was obtained from Ab-
cam. Rabbit polyclonal antibody to pS6 Ser 235/236 was obtained from
Cell Signaling. Alexa 488-conjugated donkey anti-rabbit immunoglobulin
G (IgG) Fab02 was from Life Technologies. 3H-acetate was obtained from
Perkin Elmer.
Rapamycin was purchased from LC laboratories and PP242 was from
Chemdea. 2-DG was purchased from Carbosynth. Metformin and DON were
purchased from Sigma-Aldrich. For all in vivo experiments, individual meta-
bolic inhibitors were dissolved in PBS and administrated intraperitoneally.
Cell Culture
Splenocytes or T cells were cultured in 45%RPMI 1640 and 45%Eagle Hank’s
amino acids media supplemented with 10% fetal bovine serum, penicillin/
streptomycin, glutamine, and basal medium Eagle. For proliferation studies,
T cells were labeled with 5 mM eFluor 670 cell proliferation dye (eBioscience).
Splenocytes were stimulated with anti-CD3 (1 mg/ml). For isolated T cell stim-
ulation, flat-bottomed plates were coated with anti-CD3 (5 mg/ml) diluted in
PBS and soluble anti-CD28 (2 mg/ml). For preparation of pre-activated CD4+
T cells, splenocytes from 5C.C7 mice were stimulated with 5 mM PCC peptide
in complete medium for 48 hr. Mouse recombinant IL-2 (1 ng/ml; Peprotech)
was then added to the culture. After 5–7 days, live cells were isolated by a Fi-
coll gradient (GE Healthcare).
Extracellular Flux Analysis
Cells were initially plated to XF assay medium, modified DMEM (Seahorse
Bioscience) containing 25 mM glucose, 2 mM L-glutamine, and 1 mM sodium
pyruvate and incubated in a non-CO2 incubator at 37
C for 30 min. The OCR
and ECAR were measured at 37C in an XF96 extracellular flux analyzer
(Seahorse Bioscience) using manufacturer-recommended protocols. After
baseline measurements, the OCR and ECARweremeasured after sequentially
adding anti-CD3 (2 mg/ml)/CD28 (2 mg/ml)/cross-linking IgG1 (1 mg/ml) and
metabolic inhibitors into each well to the indicated final concentrations using
the included ports on the XF96 cartridges. All data were collected using the
XF Reader software from Seahorse Bioscience.
Adoptive Transfers
CD8+ (or CD4+) T cells were harvested fromOT-I (or OT-II) mice and purified by
negative selection with CD8+ (or CD4+) MACS cell isolation protocol (Miltenyi
Biotec). 1 3 106 purified CD8+ (or CD4+) T cells were then injected intrave-
nously into Thy1.2+ C57BL/6 recipients. Vaccinia-OVA (1 3 106 plaque-form-
ing units) was simultaneously administered by injection into the retro-orbital
venous sinus.
Glutaminase Activity Analysis
Glutaminase activity measurement was adapted from previously described
protocols (Thomas et al., 2014). Briefly, T cells were lysed in ice-cold potas-
sium phosphate buffer (45 mM, pH 8.2) containing protease inhibitors (Roche,
Complete Protease Inhibitor Cocktail, 1 tablet in 50 ml) and incubated with 3H-
glutamine (0.03 mM, 0.91 mCi) for 90 min at room temperature. The reactions
were carried out in 50 ml reaction volumes in a 96-well microplate. At the
end of the reaction period, the assay was terminated upon the addition of imid-
azole buffer (20mM, pH 7). 96-well spin columns packedwith strong anion ion-
exchange resin (AG 1-X2 Resin, 200–400 mesh, chloride form; Bio-Rad) were
used to separate the substrate and the reaction product. Un-reacted 3H-gluta-
mine was removed by washing with imidazole buffer. 3H-glutamate, the reac-
tion product, was then eluted with 0.1 N HCl and analyzed for radioactivity
using Perkin Elmer’s TopCount instrument in conjunction with their 96-well
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Flow Cytometry, Intracellular Cytokine Staining, and ELISA
Flow cytometry data were acquired with a FACS Calibur (BD Biosciences) and
were analyzed with FlowJo7.6 software (Tree Star). For intracellular staining,
cells were stimulated at 37C for 4 hr in the presence of Monensin (GolgiStop;
BD Biosciences), phorbol 12-myristate 13- acetate (PMA; Sigma-Aldrich), and
ionomycin (Sigma-Aldrich). Cells were surface stained and underwent fixation/
permeabilization with either the Cytofix/Cytoperm kit (BD Biosciences) or the
Fixation/Permeabilization kit (eBioscience), followed by staining for intracel-
lular cytokines. Gates were determined appropriately through the use of
unstimulated control cells. Voltages were determined from unstained controls.
IFN-g concentration in the supernatant of cell cultures was analyzed by ELISA
as recommended by the manufacturer (eBioscience). Cell viability was deter-
mined by 7-aminoactinomycin D (7-AAD; BD Biosciences) exclusion.
In Vivo Cytotoxicity Assay
Splenocytes from WT mice were labeled with either 20 mM or 2 mM CFSE
(Invitrogen). The CSFEhigh cells were pulsed with class I OVA peptide
(10 mM). Equal numbers (5 3 106 cells) of peptide-pulsed CFSEhigh cells
and unpulsed CFSElow cells were co-administered intravenously into synge-
neic host mice that had been previously (day –7) immunized with vaccinia-
OVA (1 3 106 plaque-forming units). After 10 hr, splenocytes were isolated
from host spleens. The two target populations are distinguished based on
the differences in their CFSE intensity by flow cytometry. The loss of pep-
tide-pulsed target cells is indicative of cytotoxicity. The ratio of pulsed to un-
pulsed target cells in the indicated groups of mice was calculated and the
percent killing was determined by using the formula: [1 – (ratio in experimental
mouse/ratio in naive mouse)] 3 100%.
Lipid Biosynthesis Assay
Naive and preactivated T cells from 5C.C7 mice were incubated with 3H-ace-
tate (0.6 mCi per 1 million cells) in culture media containing anti-CD3/anti-
CD28/cross-linking, vehicle (PBS), 2-DG, metformin, DON, or triple therapy.
After a 4-hr incubation at 37C, total cellular lipids were extracted with chloro-
form/methanol by the Folch method (Folch et al., 1957), and radioactivity was
counted by liquid scintillation and normalized to mg protein.
S6 Ribosomal Protein Phosphorylation Assay
Splenocytes fromWTC57BL/6micewere stimulatedwith anti-CD3 (1 mg/ml) or
anti-CD28 (2 mg/ml), cross-linked with antibody to hamster IgG1 (0.75 mg/ml),
and combined with vehicle, rapamycin, PP242, and triple therapy for 30 min.
The cells were stained using rabbit polyclonal antibody to S6 ribosomal protein
Ser 235/236 and donkey anti-rabbit labeled secondary antibody.
Murine Skin Transplantation
BALB/c mice served as skin donors, and C57BL/6 mice serve as allograft re-
cipients. Full-thickness skin grafts were harvested from the back and then
fixed on the thoracic flank of recipient mice with simple separate stitches.
The size of transplanted grafts was 1 3 1 cm2. Grafts were observed every
day after the removal of the bandage at day 7 and considered rejected when
R90% of the graft tissue became necrotic. We observed the MST of skin
grafts. Seven days after surgery, skin tissue from the transplantation site
was collected for optical microscopy after H&E staining.
Murine Heterotopic Heart Transplantation
BALB/c mice served as heart donors, and C57BL/6 mice serve as allograft re-
cipients. Either abdominal or cervical heterotopic heart transplantation was
performed according to previously published methods (Corry et al., 1973;
Oberhuber et al., 2014). Functionality of the transplanted heart was monitored
daily by palpation. Clinical rejection was defined by cessation of palpable
heartbeats and confirmed by autopsy. Loss of graft function within 48 hr of
transplantation was considered as a technical failure, and animals in which
this occurred were omitted from the analysis.
Statistical Analysis
Prism software version 5.0 (GraphPad Software) was used for statistical ana-
lyses, including unpaired Student’s t test, two-way ANOVA, and log-rank anal-
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